Anti hair loss supplement Setipiprant Cas 866460-33-5 Setipiprant CAS NO.866460-33-5

XAZB Biotech Co., Ltd is specialized in researching, producing and selling herbal extract and API powder, which are mainly used in nutraceutical, cosmetic, beverage and food additives etc.
Owing plant base, extracting and purifying in GMP workshop, concentrating on the quality and cost each link. That XAZB Biotech is aiming of benefiting the world with lowest price but best products.
We are keeping overcritical on the quality and persisting in the profession all the time. XAZB owns two standardized production workshops, advanced multifunction extractors and juice concentrate equipment, covering 12,000m2. annual dried material processed 950MT, monthly production ability 60MT. 32 scientists are in R&D team. We have strict QC standards and perfect quality guarantee system, GMP certified, also SO9001 and Halal certified. 
We also build an integrative marketing center in Xi'an city, China, involving in research, test, sale and service. With full qualification and exporting experience, our products are widely sold to more than 40 countries from Europe, America, Southeast Asia, Oceania and so on.

Setipiprant is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly